Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 4/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | DRD4 | P21917 | 3/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7520395 | 0.86 | CHRNB2 (0.55) | CHRNB2CHRNA4ACHEGSK3BMAOA | |
| SCHEMBL7521464 | 0.86 | ACHE (0.52) | CHRNB2CHRNA4ACHEGSK3BMAOA | |
| SCHEMBL7516953 | 0.83 | DRD4 (0.48) | ACHEDRD2DRD4DRD3 | |
| SCHEMBL7464246 | 0.81 | ROCK1 (0.54) | ACHEGSK3BMAOAMAOB | |
| SCHEMBL7464417 | 0.81 | ROCK1 (0.54) | ACHEGSK3BMAOAMAOB | |
| SCHEMBL29960864 | 0.79 | ACHE (0.53) | ACHEGSK3BMAOAMAOB | |
| SCHEMBL28512442 | 0.79 | ACHE (0.53) | ACHEGSK3BMAOAMAOB | |
| SCHEMBL19959133 | 0.78 | CHRNB2 (0.62) | CHRNB2CHRNA4 | |
| SCHEMBL28514129 | 0.77 | ACHE (0.51) | ACHEGSK3BMAOAMAOB | |
| SCHEMBL29318739 | 0.77 | CHRNB2 (0.57) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020151712-A1 | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission | LIN NAN-HORNG (US) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151712-A1 | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission | GAP43, SLC18A2, GABRE | CHRNB2 16/4885CHRNA4 12/4885ACHE 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.